Medidata Solutions ((MDSO)), Veeva Systems Inc ((VEEV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The clinical study titled Clinical Study of Partially Hydrolysed Protein Infant Formula on Trans-epidermal Water Loss (TEWL) aims to evaluate the effect of partially hydrolysed whey protein formula on skin barrier function in infants, specifically measuring Trans-epidermal Water Loss (TEWL). Conducted by Société des Produits Nestlé with collaboration from Medidata Solutions, Veeva Systems, and others, this study is significant for its potential impact on infant nutrition and skin health.
The study tests two dietary supplements: Intact Cow’s Milk Protein Formula and Partially Hydrolysed Whey Formula. The purpose is to determine if the partially hydrolysed formula can reduce TEWL compared to the intact cow’s milk formula, potentially offering a preventive measure against atopic dermatitis.
This interventional study follows a randomized, open-label, parallel design with no masking. Its primary purpose is to explore the effects of dietary interventions on infant skin health, providing insights into preventive strategies for atopic dermatitis.
Key dates include the study’s start on June 6, 2021, and its completion, with the last update submitted on June 24, 2025. These dates are crucial for tracking the study’s progress and assessing its outcomes.
The study’s findings could influence the stock performance of Medidata Solutions and Veeva Systems by enhancing their reputation in clinical research support. This could also shift investor sentiment positively, given the growing interest in infant health solutions. Competitors in the infant formula market may need to consider similar research to stay competitive.
The study is completed, and further details are available on the ClinicalTrials portal.